Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Elevated transglutaminase 2 activity is associated with hypoxia-induced experimental pulmonary hypertension in mice.

DiRaimondo TR, Klöck C, Warburton R, Herrera Z, Penumatsa K, Toksoz D, Hill N, Khosla C, Fanburg B.

ACS Chem Biol. 2014 Jan 17;9(1):266-75. doi: 10.1021/cb4006408. Epub 2013 Nov 5.

2.

Role of hypoxia-induced transglutaminase 2 in pulmonary artery smooth muscle cell proliferation.

Penumatsa KC, Toksoz D, Warburton RR, Hilmer AJ, Liu T, Khosla C, Comhair SA, Fanburg BL.

Am J Physiol Lung Cell Mol Physiol. 2014 Oct 1;307(7):L576-85. doi: 10.1152/ajplung.00162.2014. Epub 2014 Aug 15.

3.

Activation and inhibition of transglutaminase 2 in mice.

Dafik L, Albertelli M, Stamnaes J, Sollid LM, Khosla C.

PLoS One. 2012;7(2):e30642. doi: 10.1371/journal.pone.0030642. Epub 2012 Feb 2.

4.

Development of Potent and Selective Tissue Transglutaminase Inhibitors: Their Effect on TG2 Function and Application in Pathological Conditions.

Badarau E, Wang Z, Rathbone DL, Costanzi A, Thibault T, Murdoch CE, El Alaoui S, Bartkeviciute M, Griffin M.

Chem Biol. 2015 Oct 22;22(10):1347-61. doi: 10.1016/j.chembiol.2015.08.013. Epub 2015 Oct 9.

5.

Tissue transglutaminase promotes serotonin-induced AKT signaling and mitogenesis in pulmonary vascular smooth muscle cells.

Penumatsa K, Abualkhair S, Wei L, Warburton R, Preston I, Hill NS, Watts SW, Fanburg BL, Toksoz D.

Cell Signal. 2014 Dec;26(12):2818-25. doi: 10.1016/j.cellsig.2014.09.002. Epub 2014 Sep 15.

6.

Transglutaminase 2-mediated serotonylation in pulmonary hypertension.

Penumatsa KC, Fanburg BL.

Am J Physiol Lung Cell Mol Physiol. 2014 Feb 15;306(4):L309-15. doi: 10.1152/ajplung.00321.2013. Epub 2013 Dec 27. Review.

7.

Fluorescent probes of tissue transglutaminase reveal its association with arterial stiffening.

Chabot N, Moreau S, Mulani A, Moreau P, Keillor JW.

Chem Biol. 2010 Oct 29;17(10):1143-50. doi: 10.1016/j.chembiol.2010.06.019.

8.

Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2.

Klöck C, Jin X, Choi K, Khosla C, Madrid PB, Spencer A, Raimundo BC, Boardman P, Lanza G, Griffin JH.

Bioorg Med Chem Lett. 2011 May 1;21(9):2692-6. doi: 10.1016/j.bmcl.2010.12.037. Epub 2010 Dec 16.

9.

Transglutaminase inhibitors attenuate vascular calcification in a preclinical model.

Beazley KE, Banyard D, Lima F, Deasey SC, Nurminsky DI, Konoplyannikov M, Nurminskaya MV.

Arterioscler Thromb Vasc Biol. 2013 Jan;33(1):43-51. doi: 10.1161/ATVBAHA.112.300260. Epub 2012 Nov 1.

10.

Transglutaminase 2 and its role in pulmonary fibrosis.

Olsen KC, Sapinoro RE, Kottmann RM, Kulkarni AA, Iismaa SE, Johnson GV, Thatcher TH, Phipps RP, Sime PJ.

Am J Respir Crit Care Med. 2011 Sep 15;184(6):699-707. doi: 10.1164/rccm.201101-0013OC. Epub 2011 Jun 23.

11.

A novel inhibitor of inducible nitric oxide synthase, ONO-1714, does not ameliorate hypoxia-induced pulmonary hypertension in rats.

Jiang BH, Maruyama J, Yokochi A, Mitani Y, Maruyama K.

Lung. 2007 Sep-Oct;185(5):303-8. Epub 2007 Aug 25.

PMID:
17721804
12.

Role of transglutaminase 2 in celiac disease pathogenesis.

Klöck C, Diraimondo TR, Khosla C.

Semin Immunopathol. 2012 Jul;34(4):513-22. doi: 10.1007/s00281-012-0305-0. Epub 2012 Mar 22. Review.

13.

An unprecedented dual antagonist and agonist of human Transglutaminase 2.

Yi MC, Palanski BA, Quintero SA, Plugis NM, Khosla C.

Bioorg Med Chem Lett. 2015 Nov 1;25(21):4922-6. doi: 10.1016/j.bmcl.2015.05.006. Epub 2015 May 15.

14.

A1 adenosine receptor-induced phosphorylation and modulation of transglutaminase 2 activity in H9c2 cells: A role in cell survival.

Vyas FS, Hargreaves AJ, Bonner PL, Boocock DJ, Coveney C, Dickenson JM.

Biochem Pharmacol. 2016 May 1;107:41-58. doi: 10.1016/j.bcp.2016.03.016. Epub 2016 Mar 21.

PMID:
27005940
15.

Tissue Transglutaminase contributes to experimental multiple sclerosis pathogenesis and clinical outcome by promoting macrophage migration.

van Strien ME, de Vries HE, Chrobok NL, Bol JG, Breve JJ, van der Pol SM, Kooij G, van Buul JD, Karpuj M, Steinman L, Wilhelmus MM, Sestito C, Drukarch B, Van Dam AM.

Brain Behav Immun. 2015 Nov;50:141-54. doi: 10.1016/j.bbi.2015.06.023. Epub 2015 Jun 29.

PMID:
26133787
16.

Development of carbon-11 labeled acryl amides for selective PET imaging of active tissue transglutaminase.

van der Wildt B, Wilhelmus MM, Bijkerk J, Haveman LY, Kooijman EJ, Schuit RC, Bol JG, Jongenelen CA, Lammertsma AA, Drukarch B, Windhorst AD.

Nucl Med Biol. 2016 Apr;43(4):232-42. doi: 10.1016/j.nucmedbio.2016.01.003. Epub 2016 Feb 2.

PMID:
27067043
17.

The role of NADPH oxidase in chronic intermittent hypoxia-induced pulmonary hypertension in mice.

Nisbet RE, Graves AS, Kleinhenz DJ, Rupnow HL, Reed AL, Fan TH, Mitchell PO, Sutliff RL, Hart CM.

Am J Respir Cell Mol Biol. 2009 May;40(5):601-9. doi: 10.1165/2008-0145OC. Epub 2008 Oct 23.

18.

Effects of transglutaminase 2 inhibition on ventilator-induced lung injury.

Suh IB, Yoon DW, Oh WO, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, Lee SY, Shin C, Shim JJ, In KH, Kang KH, Kim JH.

J Korean Med Sci. 2014 Apr;29(4):556-63. doi: 10.3346/jkms.2014.29.4.556. Epub 2014 Apr 1.

19.

Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules.

Olsen KC, Epa AP, Kulkarni AA, Kottmann RM, McCarthy CE, Johnson GV, Thatcher TH, Phipps RP, Sime PJ.

Am J Respir Cell Mol Biol. 2014 Apr;50(4):737-47. doi: 10.1165/rcmb.2013-0092OC.

20.

Activation of transglutaminase type 2 for aortic wall protection in a rat abdominal aortic aneurysm formation.

Munezane T, Hasegawa T, Suritala, Tanaka A, Okada K, Okita Y.

J Vasc Surg. 2010 Oct;52(4):967-74. doi: 10.1016/j.jvs.2010.04.049. Epub 2010 Jul 7.

Supplemental Content

Support Center